Skip to main content
. 2018 Sep 11;16(5):4283–4288. doi: 10.3892/etm.2018.6721

Figure 2.

Figure 2.

RvD1 shows no cytotoxicity on MG-63 cells. To study whether RvD1 has toxic effects on the human osteoblastic osteosarcoma cell line MG-63, MG-63 cells were pretreated with different concentrations of RvD1 (50, 100, 200 nM) for 2 h, then these cells were treated without (A) or with (B) 1 µg/ml LPS for 48 h. Then, cell viability of MG-63 cells was measured by MTT assay. Control, Cells Without any treatment; Vehicle control, Cells treated with 0.1% ethanol; RvD1 50, RvD1 100, RvD1 200: 50, 100 and 200 nM RvD1 treatment group. LPS, 1 µg/ml LPS treatment group; LPS + vehicle, 1 µg/ml LPS + 0.1% ethanol treatment group; LPS + RvD1 50, 1 µg/ml LPS + 50 nM RvD1 treatment group; LPS + RvD1 100, 1 µg/ml LPS + 100 nM RvD1 treatment group; LPS + RvD1 200, 1 µg/ml LPS + 200 nM RvD1 treatment group. *P<0.05 vs. Control; #P<0.05 vs. LPS. RvD1, resolvin D1.